Ana Lacerda

Appearances

UPADACITINIB IMPROVES ENDOSCOPIC OUTCOMES IN PATIENTS WITH MODERATE TO SEVERELY ACTIVE CROHN’S DISEASE IRRESPECTIVE OF PREVIOUS FAILURE TO RESPOND TO BIOLOGICS OR CONVENTIONAL THERAPIES
Date
May 9, 2023
BACKGROUND: After successful induction, a subset of patients with Crohn’s disease (CD) experience a secondary loss of response (LoR) to ustekinumab (UST) maintenance therapy. Dose intensification may assist in regaining response…
Presenter
Brian Feagan
Western University
Speakers
Sara Horst
Gerald Dryden
James Lindsay
Barts & The London School of Medicine and Dentistry
Marc Ferrante
Elena Dubcenco
Ana Lacerda
Sharanya Ford
Samuel Anyanwu
Qian Zhou
Jianzhong Liu
Minhu Chen
Stefan Schreiber
EFFICACY AND SAFETY OF UPADACITINIB FOR THE TREATMENT OF FISTULAS AND FISSURES IN PATIENTS WITH CROHN’S DISEASE
Date
May 9, 2023
BACKGROUND AND AIMS: A treat-to-target (TTT) strategy of striving for symptomatic and endoscopic remission is recommended for the management of inflammatory bowel diseases (IBD). Yet, real-world uptake of TTT strategies has been modest…
Presenter
Jean Frederic Colombel
Icahn School of Medicine at Mount Sinai
Speakers
Peter Irving
Florian Rieder
Cleveland Clinic Foundation
Remo Panaccione
David Schwartz
Ryohei Hayashi
Xuan Zhu
Ana Lacerda
Elena Dubcenco
Elena Marced
Patrick Hecht
Tian Feng
Sofie Berg
Walter Reinisch